Petr Arenberger
Overview
Explore the profile of Petr Arenberger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
1159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Diab A, Ascierto P, Maio M, Abdel-Wahab R, Negrier S, Mortier L, et al.
J Clin Oncol
. 2025 Mar;
:JCO2400727.
PMID: 40048691
Purpose: There are limited treatment options for advanced melanoma that have progressed during or after immune checkpoint inhibitor therapy. Intratumoral (IT) immunotherapy may improve tumor-specific immune activation by promoting local...
2.
Stefanis A, Fialova A, Arenberger P
Skin Appendage Disord
. 2025 Feb;
11(1):1-8.
PMID: 39911978
Introduction: Alopecia areata (AA) is associated with thyroid dysfunction and abnormal levels of thyroglobulin and thyroid peroxidase autoantibodies. One study detected high prevalence of thyrotropin receptor antibodies (TRAbs) in AA...
3.
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al.
Eur J Cancer
. 2024 Dec;
215:115153.
PMID: 39709737
A unique collaboration of multi-disciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), and the European Organization of Research and Treatment of Cancer (EORTC) was...
4.
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al.
Eur J Cancer
. 2024 Dec;
215:115152.
PMID: 39700658
This guideline was developed in close collaboration with multidisciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF) and the European Organization for Research and Treatment...
5.
Stefanis A, Dolezal T, Gkalpakiotis S, Arenberger P
J Cosmet Dermatol
. 2024 Nov;
24(2):e16666.
PMID: 39564906
Introduction: Alopecia areata is a common autoimmune disease which results in reversible hair loss. Janus kinase inhibitors are prescribed for severe alopecia areata with encouraging results. There are no studies...
6.
Szepietowski J, Kemeny L, Mettang T, Arenberger P
Dermatol Ther (Heidelb)
. 2024 Oct;
14(11):3033-3046.
PMID: 39422853
Introduction: There is an unmet need for effective topical therapies for patients with uremic xerosis and chronic kidney disease-associated pruritus (CKD-aP). The long-term efficacy and tolerability of an emollient containing...
7.
Stefanis A, Arenberger P, Arenbergerova M, Rigopoulos D
Skin Appendage Disord
. 2024 Oct;
10(5):376-382.
PMID: 39386300
Introduction: Androgenetic alopecia (AGA) is the most common type of hair loss. Platelet-rich plasma (PRP) and mesotherapy (MZT) injections of various solutions fortified with growth factors are popular treatment options...
8.
Pasek M, Kopecky J, Tretera V, Arenberger P, Arenbergerova M
J Eur Acad Dermatol Venereol
. 2024 Sep;
PMID: 39258869
No abstract available.
9.
Weber J, Del Vecchio M, Mandala M, Gogas H, Arance A, Dalle S, et al.
J Clin Oncol
. 2024 Aug;
42(31):3702-3712.
PMID: 39102624
Purpose: In phase III CheckMate 238, adjuvant nivolumab significantly improved recurrence-free survival compared with ipilimumab in patients with resected stage IIIB-C/IV melanoma without a significant difference in overall survival (OS)....
10.
Trzeciak M, Rudnicka L, Arenberger P, Engin B, Lvov A, Alper S, et al.
Front Med (Lausanne)
. 2024 Jul;
11:1402493.
PMID: 38962737
Background: There is limited insight into the current disease burden and everyday clinical management of moderate-to- severe AD in Poland, Czechia, Russia, and Turkiye. Therefore, this study aimed to get...